je.st
news
Tag: merck
Firkins named Merck executive director of U.S. Food Animal Marketing
2016-06-30 06:00:00| National Hog Farmer
Merck Animal Health announces that Todd Firkins has joined the company as the executive director of U.S. Food Animal Marketing. With more than 20 years’ experience in the animal health industry, Firkins brings an extensive background in sales, marketing and management, as well as considerable knowledge of our business. read more
Tags: food
marketing
director
executive
Merck KGaA, Darmstadt, Germany, Receives Frost & Sullivan Award for Meoxal and Xirallic NXT ...
2016-06-29 17:24:00| Coatings World Breaking News
Tags: germany
award
receives
sullivan
Merck and Moderna Announce Strategic Collaboration to Advance Novel mRNA-Based Personalized Cancer Vaccines with KEYTRUDA (pembrolizumab) for the Treatment of Multiple Types of Cancer
2016-06-29 13:00:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. & CAMBRIDGE, Mass. Collaboration Combines Mercks Leadership in Immuno-Oncology with Modernas Pioneering mRNA Vaccine Technology and Rapid Cycle Time, Small-Batch GMP Manufacturing Capabilities KENILWORTH, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Moderna Therapeutics today announced a strategic collaboration and license agreement to develop and commercialize novel messenger RNA (mRNA)-based personalized cancer vaccines. Language: English Contact: Merck Media:Pamela Eisele, 267-305-3558orCourtney Ronaldo, 908-236-1108orInvestors:Teri Loxam, 908-740-1986orJustin Holko, 908-740-1879or Moderna Media:Liz Melone, 617-256-6622orInvestors:Maren Winnick, 617-674-5297 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: of
types
multiple
treatment
Merck Receives CHMP Positive Opinion for KEYTRUDA (pembrolizumab) for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
2016-06-27 12:00:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. Opinion Based on Data from KEYNOTE-010, Which Showed Superior Overall Survival Compared to Chemotherapy in Previously-Treated Patients Whose Tumors Express PD-L1 KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in adults whose tumors express PD-L1 and who have received at least one prior chemotherapy regimen. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Courtney Ronaldo, 908-236-1108orInvestor:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: advanced
positive
cell
opinion
Merck to Hold Second-Quarter 2016 Sales and Earnings Conference Call on July 29
2016-06-24 14:00:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, will hold its second-quarter 2016 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EDT on Friday, July 29. During the call, company executives will provide an overview of Mercks performance for the quarter. Language: English Contact: MerckMedia:Lainie Keller, 908-236-5036orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Sites : [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] next »